A PU.1 suppressive target gene, metallothionein 1G, inhibits retinoic acid-induced NB4 cell differentiation

PLoS One. 2014 Jul 29;9(7):e103282. doi: 10.1371/journal.pone.0103282. eCollection 2014.

Abstract

We recently revealed that myeloid master regulator SPI1/PU.1 directly represses metallothionein (MT) 1G through its epigenetic activity of PU.1, but the functions of MT1G in myeloid differentiation remain unknown. To clarify this, we established MT1G-overexpressing acute promyelocytic leukemia NB4 (NB4MTOE) cells, and investigated whether MT1G functionally contributes to all-trans retinoic acid (ATRA)-induced NB4 cell differentiation. Real-time PCR analyses demonstrated that the inductions of CD11b and CD11c and reductions in myeloperoxidase and c-myc by ATRA were significantly attenuated in NB4MTOE cells. Morphological examination revealed that the percentages of differentiated cells induced by ATRA were reduced in NB4MTOE cells. Since G1 arrest is a hallmark of ATRA-induced NB4 cell differentiation, we observed a decrease in G1 accumulation, as well as decreases in p21WAF1/CIP1 and cyclin D1 inductions, by ATRA in NB4MTOE cells. Nitroblue tetrazolium (NBT) reduction assays revealed that the proportions of NBT-positive cells were decreased in NB4MTOE cells in the presence of ATRA. Microarray analyses showed that the changes in expression of several myeloid differentiation-related genes (GATA2, azurocidin 1, pyrroline-5-carboxylate reductase 1, matrix metallopeptidase -8, S100 calcium-binding protein A12, neutrophil cytosolic factor 2 and oncostatin M) induced by ATRA were disturbed in NB4MTOE cells. Collectively, overexpression of MT1G inhibits the proper differentiation of myeloid cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / genetics
  • Antigens, CD / metabolism
  • Cell Differentiation / drug effects*
  • Cell Line, Tumor
  • G1 Phase Cell Cycle Checkpoints / drug effects
  • G1 Phase Cell Cycle Checkpoints / genetics
  • Gene Expression
  • Gene Expression Profiling
  • Gene Expression Regulation*
  • Humans
  • Immunophenotyping
  • Leukemia, Promyelocytic, Acute / genetics
  • Leukemia, Promyelocytic, Acute / metabolism
  • Leukemia, Promyelocytic, Acute / pathology
  • Metallothionein / genetics*
  • Proto-Oncogene Proteins / metabolism*
  • Reproducibility of Results
  • Trans-Activators / metabolism*
  • Tretinoin / pharmacology*

Substances

  • Antigens, CD
  • MT1G protein, human
  • Proto-Oncogene Proteins
  • Trans-Activators
  • proto-oncogene protein Spi-1
  • Tretinoin
  • Metallothionein

Grants and funding

This work was supported in part by a Grant-in-Aid for Scientific Research (No. 23590687 and 26460685) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Takeda Science Foundation, and a foundation from Kitasato University School of Allied Health Sciences (Grant-in-Aid for Research Project, No. 2012-1002, 2013-1001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.